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Abstract: Nanostructured agglomerated vesicles encapsulating ciproﬂ  oxacin were evaluated for 
modulated delivery from the lungs in a healthy rabbit model. An aliphatic disulﬁ  de crosslinker, 
cleavable by cysteine was used to form cross-links between nanosized liposomes to form the 
agglomerates. The blood levels of drug after pulmonary instillation of free ciproﬂ  oxacin, liposo-
mal ciproﬂ  oxacin, and the agglomerated liposomes encapsulating ciproﬂ  oxacin were evaluated. 
The liposomes and agglomerated vesicles showed extended release of drug into the blood over 
24 hours, while the free ciproﬂ  oxacin did not. The agglomerates also allowed modulation of 
the drug release rate upon the introduction of cysteine into the lungs post-drug instillation; the 
cysteine-cleavable agglomerates accelerated their drug release rate, indicated by an increased 
level of drug in the blood. This technology holds promise for the post-administration modulation 
of antibiotic release, for the prevention and treatment of pulmonary and systemic infections.
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Introduction
Agglomerated vesicles for pulmonary delivery
In previous work (Bhavane et al 2003) the concept of drug-containing nanoparticles 
that are chemically cross-linked to each other, to create porous agglomerates (AVT or 
Agglomerated Vesicle Technology), was introduced and demonstrated in vitro. The 
core particles for making the agglomerate could be polymeric nanoparticles with drug 
incorporated into them, or even drug nanoparticles to which the spacer arms have been 
conjugated. A particularly versatile choice of core nanoparticle is a liposome, that can 
conveniently be fabricated to present a variety of ligands at the distal ends of spacer 
PEG chains (Zalipsky 1993). The ligands at the distal ends of the spacer arms are then 
used to cross-link the nanoparticles into larger clusters or agglomerates, by using a 
suitable chemical linker. The preparation, size, aerodynamic characteristics, and drug 
release characteristics of such agglomerates in vitro were also demonstrated (Bhavane 
et al 2003). It was shown that by making the cross-links cleavable, post-administration 
modulation of the drug release rate could be achieved by selective cleavage of the 
cross links. A description of the agglomeration of liposomes with a cross-linker and the 
subsequent cleavage of the linkages between the liposomes is illustrated in Figure 1. 
We have termed this technology as Agglomerated Vesicle Technology (AVT).
Progressive cleavage in vitro showed increased release, which even exceeded that 
from the unagglomerated particles (Bhavane et al 2003). A possible reason for this 
unexpected increase in release could be attributed to the disruption in the structure 
of agglomerate. Particles in the lung, or in stirred sample in vivo, experience shear 
forces due to the motion of the suspending ﬂ  uid. This in turn could lead to the disrup-
tion of the liposome bilayers due to shear forces acting over the entire length scale of International Journal of Nanomedicine 2007:2(3) 408
Bhavane et al
the agglomerate, tearing out the lipid anchors from the ve-
sicular bilayer and causing gross leakage from the disrupted 
liposomes.
One of the major shortcomings of these agglomerated 
vesicles made with the crosslinker DTBP was the need 
for aggressive cleaving agents to cleave the cross links. In 
these ﬁ  rst-generation agglomerates, DTT (dithiothreitol) 
was the cleaving agent used. In subsequent work therefore 
(Karathanasis et al 2005) a dithiobenzyl linkage cleavable by 
a biologically acceptable agent (cysteine) was developed. The 
release of ciproﬂ  oxacin from such agglomerates was demon-
strated. In a departure from the behavior of the DTT cleavable 
particles, the cysteine-cleavable particles were shown to 
release drug continuously, possibly due to ongoing cleavage 
of the linkages by thiols present in the release experiment 
medium (pulmonary surfactant replacement, Survanta®). 
When administered in vivo, these particles faciliated post-
administration-modulation of drug release. Thus, insulin 
release with the possibility of controlled post-adminstration 
changes in the release rate was demonstrated for the ﬁ  rst time 
(Karathanasis et al 2006). However, continuing concerns 
about the cleavage of this linkage by endogenous cysteine 
remained. This therefore led us to seek alternative linkages 
that would not cleave in the presence of endogenous thiols, 
but would cleave upon the administration of exogenous 
cysteine, at levels higher than that present normally in the 
body. The availability of such a linkage would facilitate 
more complete control over the release of drug from the 
nanostructured AVT particles.
In this work therefore, an aliphatic disulfide DTSSP 
was used to evaluate drug release upon cysteine introduc-
tion in vivo. In our previous studies of AVT agglomerates 
(Karathanasis et al 2005) with the dithiobenzyl linkage, the 
aliphatic disulﬁ  de DTSSP was used as a cross-linker. When 
the cleavage of the particles by cysteine was attempted by the 
addition of exogenous cysteine, cleavage was indeed observed, 
but it was not clear whether the cleavage was occurring at the 
dithiobenzyl site or at the aliphatic disulﬁ  de of the DTSSP. 
In this work therefore, the cleavage of the aliphatic disulﬁ  de 
– DTSSP was studied in vivo, as a candidate for facilitating 
selective in vivo cleavability of AVT particles.
In previous studies done in our labs (Bhavane et al 
2003), it has been shown that AVT particles with large 
geometrical sizes (1–100 + μm) exhibited aerodynamic 
Figure 1 Schematic of core particles bearing ligands (a); agglomeration of core particles by linkers to form agglomerates (b); based on the linker chemistry some can be 
cleaved in-vivo by components of lung ﬂ  uid (c).
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sizes in the respiratory size range (1–5 μm). It was also 
shown that the nebulization of these large agglomerates 
produced minimal damage to the agglomerates on the 
basis of size and encapsulation of the drug. Hence, we 
have a high degree of confidence that the AVT particles 
can be used in inhalation therapy. These particles were 
instilled in animals in this study since nebulization into 
the lungs of these animals is difficult.
Liposomal ciproﬂ  oxacin vs free 
ciproﬂ  oxacin
Ciprofloxacin, a fluoroquinolone, was chosen for this 
study because of its potential for inhaled pulmonary 
delivery. Ciprofloxacin is a potent broad-spectrum 
antibiotic having good antibacterial activity against most 
bacteria including Pseudomonas aeruginosa, Klebsi-
ella pneumoniae, Staphylococcus aureus, Streptococci, 
Mycobacterium tuberculosis, and Mycobacterium avium 
complex (Gay et al 1984; Fenlon and Cynamon 1986; 
Sanders et al 1987). While ciprofloxacin has better tissue 
penetration, phagocytic accumulation and low pH activ-
ity than most other antibiotics, it is still not sufficiently 
active against intracellular pathogens in a single dose. 
Hence, repeated doses of the drug are prescribed every 8 
to 12 hours as an oral or intravenous treatment.
Liposomal encapsulation of ciproﬂ  oxacin followed by 
pulmonary delivery however, greatly improves its efﬁ  cacy. It 
has been shown that ciproﬂ  oxacin encapsulated in liposomes 
when administered directly to the lungs as a single dose, is a 
potent treatment and prophylactic agent against pulmonary 
pathogens including intracellular ones (Webb et al 1998; 
Wong et al 2003). Wong et al also showed that the survival 
of mice infected with Francisella tularensis was improved 
when ciproﬂ  oxacin encapsulated in liposomes was aerosol-
ized into the lungs. Indeed, the liposomal drug was active 
both in “prophylactic” mode (administration pre-infection) 
and in “treatment” mode (administration post infection). 
Further, the work showed that the lung-retention of liposomal 
ciproﬂ  oxacin was higher than the free drug, leading to a bet-
ter prophylactic efﬁ  cacy in comparison to free ciproﬂ  oxacin. 
Pretreatment of mice up to 24 hours prior to bacterial chal-
lenge with liposome-encapsulated ciproﬂ  oxacin thus resulted 
in complete survival.
We anticipated that AVT particles being larger than 
liposomes would have lower susceptibility to macrophage 
uptake and therefore improve lung residence time and 
systemic bioavailability. AVT formulations, liposomal 
formulations and an unencapsulated ciprofloxacin 
formulation were therefore evaluated for release of drug 
from the lungs after instillation in healthy rabbits. Further, 
to measure lipid elimination as a function of particle size 
and correlate it to drug release, ﬂ  uorescently tagged lipo-
somes and agglomerates were instilled in the lungs of rats 
and the residual ﬂ  uorescence in lung tissue was assayed 
over a 48 hour period.
Materials and methods
Materials
1, 2-Dipalmitoyl-sn-Glycero-3-Phosphatidylcholine (DPPC) 
and methoxypoly (ethylene glycol) – distearoylphospha-
tidylethanolamine (MPEG-DSPE) were purchased from 
Genzyme Pharmaceuticals (Cambridge, MA, USA). 
Cholesterol (CHOL) was purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Distearoyl phosphoethanolamine 
[Amino (polyethylene glycol)] (DSPE-PEG-NH2) conju-
gate was purchased from Avanti Polar Lipids (Alabaster, 
AL, USA). Fluorescently tagged lipid, N-(7-nitrobenz-2-
oxa-1, 3-diazol- 4-yl)-1, 2-dihexadecanoyl-sn- glycero-
3-phosphoethanolamine (NBD-PE) was purchased from 
Invitrogen Corp. (Carlsbad, CA, USA). The cross-linkers 
dimethyl 3, 3'-dithiobispropionimidate•2HCl (DTBP) and 
3, 3'-Dithiobis[sulfosuccinimidylpropionate] (DTSSP) were 
purchased from Pierce (Rockford, IL, USA). Ciproﬂ  oxacin 
(Bayer Pharmaceutical Corp., West Haven, CT, USA) was 
purchased from a local pharmacy as Cipro-IV solution 
and puriﬁ  ed as follows: The pH of Cipro-IV solution was 
raised from 2.1 to 7 with sodium hydroxide to precipitate 
the ciproﬂ  oxacin. The suspension was then centrifuged at 
1500 × g (4000 rpm) for 10 minutes, and the supernatant 
discarded. The powder was then washed with DI water and 
centrifuged 4 times to remove lactic acid (an inert excipient 
in the iv. solution). A ﬁ  nal wash and centrifugation with 
ethanol yielded a wet powder which was collected and dried 
in a vacuum desiccator. Ciproﬂ  oxacin yield was 90%.
All other reagents were purchased from Fisher Scientiﬁ  c 
(Hampton, NH, USA).
Animals
New Zealand White male rabbits (2.9 ± 0.5 kg) were 
purchased from Myrtle Rabbitry (Thompson Station, TN, 
USA). Male Sprague Dawley rats (330–350 gm) were 
purchased from Harlan (Indianapolis, IN, USA). The 
use of animals for this study was approved by the Center 
for Laboratory Animal Medicine and Care (CLAMC) 
of UTHSC-Houston. Care and handling of the animals 
was in accordance with all policies of the United States International Journal of Nanomedicine 2007:2(3) 410
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Department of Agriculture (USDA) and U.S. Public 
Health Service (PHS).
Preparation of ciproﬂ  oxacin-loaded 
liposomes and agglomerates 
for pharmacokinetic studies
Fabrication and characterization of parent liposomes
Two separate sets of liposomes (~120 mM lipid content) 
were prepared. A lipid composition of DPPC:CHOL:
DSPE-MPEG (57:40:3, mol%) (MPEG terminated, for 
Stealth® liposomes), and DPPC:CHOL:DSPE-PEG-
NH2 (57:40:3, mol%) (Amino terminated, for making 
AVT) was used. The liposomes were extruded through 
a 400 nm polycarbonate membrane by the extrusion 
process described in previous work (Bhavane et al 
2003). The liposomes were characterized by Dynamic 
Light Scattering (DLS) using a Brookhaven Instruments 
BI-9000AT Digital Autocorrelator, a BI-200SM goni-
ometer and a Hamamatsu photomultiplier (Brookhaven 
Instruments Corp., Holtsville, NY, USA). The light source 
was a 532 nm, Ti-sapphire, frequency doubled laser. For 
the DLS measurement, the liposomal suspension was 
appropriately diluted in saline (150 mM).
Loading of ciproﬂ  oxacin into liposomes
Ciprofloxacin was loaded into the liposomes by the 
ammonium sulfate gradient method (Lasic et al 1995). 
Blank liposomes were ﬁ  rst prepared in a 400 mM ammo-
nium sulfate solution. Liposomes were diaﬁ  ltered for 1–2 
hours using 50 nm cutoff tubings with the external phase of 
the liposomes being replaced with saline (150 mM) at pH 
of ~5.3 in order to remove ethanol and non-encapsulated 
ammonium sulfate. For the remote loading procedure, 
Ciproﬂ  oxacin was dissolved in saline (60 mg/ml) at pH 4.2 
and 60 ºC, and was gradually added (0.5 ml added every 3–5 
minutes) to the liposomal suspension with the temperature 
maintained at 60 ºC. The loading was terminated after 
1 hour by rapidly dropping the temperature using an ice 
bath. The drop in temperature reduces the permeability 
of the liposome bilayer thus preventing the transfer of 
species across the bilayer and entrapping the loaded drug. 
Finally, the suspension was separated from unencapsulated 
Ciproﬂ  oxacin by overnight dialysis against saline solution 
(100 times volume of liposomes) at pH 5.3. The ﬁ  nal lipid 
content of the ciproﬂ  oxacin-loaded Stealth® liposomes 
used in the study was approximately 110 mM, and of the 
liposomes that were later agglomerated was ~50 mM.
Agglomeration of liposomes
Liposomes containing 3% PEG-NH2 conjugate in the lipid 
bilayer were agglomerated using DTBP or DTSSP as the 
linker. The amount of DTBP used was a 50 fold molar 
excess over the number of PEG-NH2 groups on the outer 
leaflet of the liposomes. The pH of the liposomes was 
raised from 5.3 to 8.5 (the optimal pH for DTBP activity 
is in the 8–9 range) with NaOH solution, and the linker 
was added to the liposomes with constant stirring for 
1.5 hours after which the pH was dropped to 5.3 to arrest 
the cross-linking reaction. DTSSP used for the agglom-
eration was a 12 fold molar excess over the PEG-NH2 
groups on the outer leaflet of the liposomes. The pH was 
raised from 5.3 to 7.4 (optimal for DTSSP crosslinking 
activity) and the linker was added to the liposomes and 
constantly stirred for 1.5 hours.
The size distribution of the agglomerates was 
determined using Fraunhofer diffraction technique on a 
Malvern Mastersizer with 100 mm lens (Malvern Instru-
ments Inc., Southborough, MA, USA). The morphology 
of the agglomerates of DTSSP preparations was examined 
by negative staining electron microscopy (EM). Copper 
grids coated with colloidion-carbon and freshly glow 
discharged were used for sample adsorption. Each grid 
was floated on a drop of sample for 5 min. Excess fluid 
was removed by blotting with a filter paper, and the grid 
was washed for 2 seconds on a drop of water, floated on 
a drop of 1% uranyl acetate for 15 seconds, and air dried 
for 2–5 minutes. All electron micrographs were taken 
with a JEOL JEM1230 electron microscope operating at 
80 kV and 56 μA beam current.
Determination of ciproﬂ  oxacin
The concentration of ciproﬂ  oxacin was determined by HPLC. 
The HPLC system consisted of a Shimadzu SCL-10Avp liq-
uid chromatograph, SPD-10Avp UV-Vis detector (278 nm) 
and SIL-10Advp auto-injector. Chromatography was carried 
out with a Waters Symmetry 5 μm C18 column (150 × 4.6 
mm) at room temperature and a mobile phase ﬂ  ow rate of 1.0 
mL/minute; The mobile phase was a mixture of 15% (v/v) 
of acetonitrile and 85% (v/v) of 25 mM sodium phosphate 
(pH ~ 2.3) buffer; The sample injection volume was 20 μL. 
Under these assay conditions, ciproﬂ  oxacin eluted within 
10 minutes.
To determine the amount of ciproﬂ  oxacin entrapped 
within liposomes, the liposomes were disrupted by methanol 
(30% of total volume) before assay. The resulting solution 
was then assayed as above.International Journal of Nanomedicine 2007:2(3) 411
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Preparation of ﬂ  uorescent tagged 
liposomes and agglomerates
Fabrication and characterization of ﬂ  uorescent 
liposomes
A lipid composition of DPPC:CHOL:DSPE-PEG-NH2:NBD-
PE (56:40:3:1, mol%) was used. After ethanol dissolution the 
lipids were hydrated with 150 mM NaCl solution. The ﬁ  nal 
lipid content of the liposomes was 50 mM. The liposomes 
were extruded through a 400 nm polycarbonate membrane 
and measured by Dynamic Light Scattering (DLS).
Agglomeration of liposomes with ﬂ  uorescent tagged 
lipids
Liposomes with a lipid content of 50 mM were agglomer-
ated using DTSSP as the linker. The amount of DTSSP used 
for the agglomeration was a 20 fold molar excess over the 
PEG-NH2 groups on the outer leaﬂ  et of the liposomes. The 
crosslinking reaction was carried out at a pH of 7.4 with 
constant stirring for 1.5 hours. The size distribution of the 
agglomerates was determined using the Fraunhofer diffrac-
tion technique.
Pharmacokinetic studies of ciproﬂ  oxacin-
loaded liposomes and agglomerates
The rabbits were anesthetized by a subcutaneous injection 
of ketamine/xylazine (40–50/5–10 mg/kg). The rabbits 
were maintained on 2% isoflurane and O2 (1 lit/minute). 
The heart rate, temperature and O2 were monitored 
periodically, and remained stable throughout the course 
of the experiment.
The marginal ear vein was accessed via an i.v. catheter 
(24 G). The catheter was taped to the ear. Using a laryngo-
scope, an endotracheal tube (size 3) was inserted into the 
trachea, with a urinary catheter acting as a guide. Insertion 
into trachea was conﬁ  rmed with a stethoscope, by pumping 
air into the lungs. The cuff of the endotracheal tube was ﬁ  lled 
with air to maintain the tube in the trachea. Additionally, the 
tube was tied to the mouth to retain it in place.
The rabbit’s head was maintained in an upright posi-
tion and drug formulation was instilled into the lungs with 
a syringe. The formulation was pushed down by forcing 
air into the lungs with the syringe several times. 2.2 to 2.8 
ml of formulation (corresponding to ciproﬂ  oxacin doses of 
17 ± 1.6 mg/kg) was instilled.
Blood was drawn from the ear vein before (time 0) and 
after instillation of drug formulation. Blood samples were 
centrifuged at 13,400 rpm for 15 minutes to separate the 
plasma from cell components. The plasma was then diluted 
1:4 times with methanol: phosphate buffer (9:1 v/v) to 
precipitate the proteins present in the sample. The resulting 
suspension was then centrifuged at 13,400 rpm in a micro-
centrifuge for 15 minutes and the supernatant was assayed 
for ciproﬂ  oxacin content by HPLC. Standard curve for 
Ciproﬂ  oxacin was determined by spiking known amounts 
of ciproﬂ  oxacin in rabbit plasma. The lowest detection limit 
by HPLC was 0.05 μg/ml.
After instillation of the formulations, the rabbits were 
maintained on 1.5% isoﬂ  urane and O2 (1 lit/minute). The 
isoﬂ  urane was stopped 2 hours after the instillation and the 
rabbits were maintained on O2 (1 lit/minute) and recovered 
from the anesthesia. The rabbits were fully awake after 5–6 
hours from sedation and returned to their cages.
The following formulations were instilled into the 
lungs:
a) Free  ciproﬂ  oxacin solution
 Ciproﬂ  oxacin was dissolved in normal saline at a con-
centration of 21.9 mg/ml. The pH of the solution was 
adjusted to approximately 3.1 to maintain ciproﬂ  oxacin 
in solution. This solution was then instilled into the lungs 
of the rabbits as described above.
b) Liposome-encapsulated  ciproﬂ  oxacin
  The instillation of the Stealth® liposomes was as described 
by the procedure above. The ﬁ  nal lipid content of the 
liposomes that were instilled was ~110 mM.
c) AVT  1
  AVT particles made with the crosslinker DTBP are 
referred to as AVT 1 in this paper. These agglomerates are 
not susceptible to cysteine cleavage. They were instilled 
according to the procedure described above. The ﬁ  nal lipid 
content of the AVT 1 that was instilled was ~50 mM.
d) AVT  2
  AVT particles made with the aliphatic disulﬁ  de linker 
DTSSP are referred to as AVT 2 in this text. Two sets 
of studies were done with these agglomerates. In the ﬁ  rst 
study the agglomerates were instilled as described above, 
and their drug release monitored. In the second study, 1 
ml cysteine (60 mg/ml) was introduced in to the lungs 
90 minutes after instillation of AVT 2. This was done in 
order to cleave the agglomerates and alter the release of 
ciproﬂ  oxacin into the blood. The rabbits recovered from 
anesthesia and were returned to their cages after 6 hours.
After 24 hours, the rabbits were anesthetized with 
ketamine/xylazine (40–50/5–10 mg/kg) and intubated again 
and cysteine solution was instilled. Blood was drawn at all 
the time points as described earlier.International Journal of Nanomedicine 2007:2(3) 412
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Lipid assay of lungs after instillation 
of particles with ﬂ  uorescent tagged lipid
Male Sprague Dawley rats were anesthetized with an 
injection of ketamine (80 mg/kg body wt.) and xylazine 
(10 mg/kg body wt.) given intraperitoneally. The rats 
were endotracheally intubated with a 16 G catheter. The 
endotracheal tube was then connected to a ventilator 
and under forced ventilations; successful intubation was 
confirmed if the chest of the rat expanded with the same 
frequency as the ventilator. 200 μL of the liposomal 
and agglomerate formulations (50 mM lipid content) 
with the fluorescent tagged lipids were instilled into the 
lungs of the rats. The total lipid dosed was 4078.78 ± 
506.07 μg/gm of lung wt. In a separate study, 100 μL of 
cysteine (60 mg/ml) was instilled after 4 minutes from 
the instillation of the cleavable agglomerates. At 2, 24, 
and 48 hours post-instillation of the liposomes and ag-
glomerates, the rats were euthanized with an overdose of 
pentobarbital (200 mg/kg) administered i.p. and the lungs 
were collected for the lipid assay.
The collected lungs were refrigerated and processed 
within a few hours of extraction. For the lipid extraction 
a modification of the method of Matot et al (2003) was 
used. Briefly, the lungs were weighed, chopped and then 
homogenized in cold chloroform/methanol (2:1 vol.) 
mixture. The homogenized tissue was filtered through 
Whatman filter paper no.1. The collected filtrate was 
then assayed for fluorescence in a SpectraMax GeminiXS 
spectrofluorometer (Molecular Devices Corp, Sunnyvale, 
CA, USA) with filter settings of 463 nm excitation and 
530 nm emission wavelengths. (calibration standards were 
made by spiking known amounts of the tagged liposomes 
into the filtrate collected from the lungs of untreated 
rats.) The fluorescence intensity associated with the 
known lipid from the liposomes was used to determine 
the amount of lipid that remained in the lungs after instil-
lation of the liposomes and the agglomerates.
Results and discussion
Characterization of liposomes by DLS
The size of the Stealth® liposomes encapsulating 
ciproﬂ  oxacin was in the range of 160 to 400 nm with a 
mean of 330 nm. The size of liposomes encapsulating 
ciproﬂ  oxacin that were agglomerated later with DTBP to 
form AVT 1, was in the range of 150–300 nm with mean 
of 260 nm. The size of the liposomes that were agglomer-
ated later with DTSSP to form AVT 2, were in the range 
of 140–350 nm with a mean at 210 nm. The liposomes 
incorporating ﬂ  uorescent tagged lipid were in the range of 
177–460 nm with a mean at 290 nm. The effective encapsu-
lation and release rate of drug from these preparations was 
not expected to be signiﬁ  cantly different.
Characterization of agglomerates
The particle size distribution, by Fraunhofer Diffraction, of 
AVT 1 and AVT 2 that were used for the pharmacokinetic 
studies, and that of the agglomerates used for the lipid assay 
studies, are shown in Figure 2. The agglomerate popula-
tions for AVT 1 and AVT 2 are broadly distributed from 
1–140 μm with somewhat different modes.
The agglomerates of DTSSP that were used for the lipid 
assay studies show a bimodal distribution from 1–125 μm, 
with one mode at 5 μm and the second one at 44 μm. 
Factors such as pH, buffer, the linker: lipid ratio, stirring 
rate, etc could affect the agglomeration process ultimately 
affecting the agglomerate size and the nanostructure of the 
agglomerate (Bhavane et al 2003; Karathanasis et al 2005). 
The differences in size and the nanostructure could in turn 
affect the release properties of the microparticle formed. 
A compact structure of the agglomerate would represent a 
high concentration of drug-bearing nanoparticles, which may 
not promote diffusive transport. On the other hand, a more 
porous, open structure would represent a lower concentration 
of drug-bearing particles, but a higher diffusive transport 
rate. Also, due to the dynamic nature of the lungs, large 
and loose agglomerates maybe more susceptible to rupture 
and consequent increase in drug release in comparison to 
smaller compact agglomerates. This would mean more drug 
being released into the systemic circulation, and a possible 
improvement in the bioavailability, as the pharmacokinetic 
studies seem to suggest so.
Figure 3 shows the negative stain electron microscope 
images of liposomes and AVT particles encapsulating 
ciprofloxacin. Figure 3a is the EM image of the parent 
liposomes with diameters around 200 nm. Since the length 
of the PEG anchor (~7 nm) is very small compared to 
the size of the liposome, linked liposomes are in close 
proximity as shown in Figures 3b–d. The agglomerates 
clearly consisted of clusters of cross-linked liposomes 
incorporating high amounts of the negative stain sug-
gesting high accessibility of the aqueous phase to the 
interior of the agglomerate structure. A heterogeneous 
structure can be seen including highly porous as well as 
compact domains within the agglomerate. As the compact 
structures were nucleated rapidly, diffusion-limitations International Journal of Nanomedicine 2007:2(3) 413
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dominated during the agglomeration reaction, resulting 
in the formation of porous structures of the compact 
“nuclei”. Similar structures are expected for all the 
agglomerates formed, since the reaction conditions for 
each were very similar. One therefore expects that drug 
release properties of each of the agglomerates would also 
be very similar to each other.
Pharmacokinetic studies with 
ciproﬂ  oxacin-loaded liposomes 
and agglomerates
Figure 4 shows the blood levels of ciprofloxacin after 
intratracheal instillation of the free ciproﬂ  oxacin, liposome-
encapsulated ciproﬂ  oxacin, AVT 1, AVT 2, and AVT 2 + 
cysteine treatment. Each data point represents the mean and 
standard deviation of the group (3 rabbits per group). The 
difference of the means between groups was veriﬁ  ed to be 
signiﬁ  cant by variance analysis (Student’s t-test). A p-value 
less than 0.05 was used to conﬁ  rm signiﬁ  cant differences at 
the 95% conﬁ  dence level.
The doses of the drug formulations instilled in the rabbits 
are tabulated in Table 1. It should be noted that ciproﬂ  oxacin 
has a very low solubility at neutral pH. Ciproﬂ  oxacin at a 
concentration of 21.9 mg/ml was instilled in the lungs in this 
study to compare with the concentrations used in experi-
ments involving liposomes and the agglomerates. To keep 
ciproﬂ  oxacin in solution at this concentration, the pH of the 
formulation was maintained at ~3.1. The rabbit treated with 
the free ciproﬂ  oxacin formulation showed signs of distress 
(heavy panting) after instillation. When the lungs were 
observed post mortem, there were signs of extensive injury 
highlighted by the darkening of the lung tissue. Hence, no 
more rabbits were used to evaluate free ciproﬂ  oxacin. The 
lung injury may be attributed to the high concentration of 
ciproﬂ  oxacin that is in immediate contact with the tissue and 
the low pH of the formulation. To the authors’ knowledge 
there are no studies reporting inﬂ  ammation of the lungs or 
toxicity effects due to administration of ciproﬂ  oxacin to the 
lungs. No such signs of damage were observed in the lungs 
of the rabbits that were used to evaluate the liposomes and 
AVT particles. It can well be argued that the damage caused 
Figure 2 Particle size distribution (measured by Fraunhofer Diffraction) of the agglomerates used in the study.
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to the lungs by the free ciproﬂ  oxacin solution may alter the 
clearance of the drug and is not a valid comparison to the 
liposomal and AVT treatment. Wong et al (2003) showed 
the advantage of liposomal ciproﬂ  oxacin treatment over free 
ciproﬂ  oxacin in a diseased animal model. For consistency 
with that study, free ciprofloxacin was evaluated in our 
work, to show the extended and modulated capabili-
ties of the AVT. Clearly the liposomes and AVT seem 
to protect the lung from considerable damage at these 
high levels.
A burst in release was observed in the case of the free 
ciproﬂ  oxacin during the 1st hour, which then rapidly dropped 
a b
c d
Figure 3 Negative stain electron microscope images (1% uranyl acetate) taken on a JEOL JEM 1230. (a) liposomes at 10 K magniﬁ  cation, scale bar 0.2 μm; (b) agglomerate 
at 10 K magniﬁ  cation, scale bar 0.2 μm; (c) agglomerate at 2 K magniﬁ  cation, scale bar 2 μm; (d) agglomerate at 4 K magniﬁ  cation, scale bar 1 μm.
Table 1 Formulation of ciproﬂ  oxacin instilled in the lungs of rabbits
Formulation Ciproﬂ  oxacin Dose (mg/kg)  Molarity of lipids (mM)  Drug: Lipid (molar)
Liposome 21.07  ±  1.64  ~120  0.664
AVT 1 17.05  ±  0.44  ~50  1.07
AVT 2 18.31±0.62  ~50  1.07
Free Ciproﬂ  oxacin 15.4  NA  NAInternational Journal of Nanomedicine 2007:2(3) 415
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to low values and eventually went to zero at the end of 
48 hours. Cmax in blood was measured to be 3.38 μg/ml. This 
rapid release can be attributed to the fact that ciproﬂ  oxacin 
is in direct contact with the tissue and is able to quickly dif-
fuse out in the blood. An assay of the lungs of the rabbit at 
the end of 48 hours indicated no ciproﬂ  oxacin remained in 
the lungs.
In the case of liposomes, AVT 1, and AVT 2, though an 
initial burst in release of drug was observed, it was much 
lower than that for free ciproﬂ  oxacin. However, the AVT 
and liposomes show that they are capable of extended drug 
release in the blood. Cmax for the liposomal formulation was 
0.34 ± 0.06 μg/ml and this level of drug in the blood was 
maintained through the 48 hour period. Cmax for AVT 1 
was observed to be 1.53 ± 0.04 μg/ml with the level gradu-
ally falling to 0.63 ± 0.08 μg/ml over 24 hours. Thus the 
entire curve for AVT 1 was higher than that for liposomes, 
indicating a much higher bioavailability. AVT 2 exhibited 
a Cmax between that for AVT 1 and liposomes (0.8 ± 0.07 
μg/ml) followed by a gradual drop to 0.24 ± 0.04 μg/ml in 24 
hours. The lower initial release-burst for the liposomes and 
AVT particles is consistent with the fact that the ciproﬂ  oxa-
cin is encapsulated within the particles and is not in direct 
contact with the lung environment. As the drug leaks out of 
the particles, it is transported rapidly to the bloodstream, but 
at no point is the free drug concentration in the lung high 
enough to cause a large spike in the blood levels as observed 
in the free ciproﬂ  oxacin case.
After instillation of cysteine at 90 minutes into the 
lungs of the rabbits treated with AVT 2, an elevation 
in release rate was observed. The Cmax attained due to 
cysteine instillation was 1.27 ± 0.22 μg/ml. The blood 
levels of drug in animals treated with AVT 2 and then 
with cysteine are significantly different (p < 0.05) from 
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Figure 4 Pharmacokinetic data for the different formulations tested in rabbits.  Arrows indicate time points when cysteine was instilled into the lungs. Inset–detail of the 
ﬁ  rst 500 minutes for the liposomes, AVT 1, AVT 2, and AVT 2 + cysteine (n = 1 for the free ciproﬂ  oxacin study. And n = 3 for the other studies). Study with liposomes and 
free ciproﬂ  oxacin was done over 2 days. The AVT studies were done over 1 day. AVT 2 + Cysteine treatment resulted in blood levels of ciproﬂ  oxacin different from AVT 2 
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those for the same formulation with no cysteine treat-
ment. The bioavailability of the AVT 2 particles is clearly 
improved after cysteine instillation as indicated by the 
increase in the AUC.
A 40% increase in total release (as measured by 
the area under the curve) was caused by the cysteine 
instillation. After 24 hours a repeat cysteine instillation 
resulted in further triggered release. However, smaller 
drug amounts were released consistent with overall lower 
residual drug content in the particles at this extended time 
post administration. The triggered release due to cysteine 
addition may be attributed to the cleaving of the disulfide 
linkages on the DTSSP that links two liposomes. This 
breakage would result in the rupture of the structure of the 
microparticle resulting in accelerated drug release. The 
areas under the concentration-time curves (AUC0 – 24) for 
AVT 1, AVT 2, AVT 2 + cysteine, and liposomes for 24 
hours were computed and are listed in Table 2. The AUC’s 
increase with the size of the particles, suggesting that the 
larger particles have an improved systemic bioavailability 
in comparison to the smaller particles.
Lipid assay of lungs after instillation 
of particles with ﬂ  uorescent tagged lipid
The measurement of lipid retained in the lungs indicated 
that there is no signiﬁ  cant difference between liposomes 
and agglomerates (Figure 5). Further, there is no systematic 
change in lipid levels during the 48 hour observation period; 
50%–60% of the initial amount of lipids dosed is observed in 
the lungs at all times. This result is similar to those of Webb 
et al (1998) who showed that after instillation of liposomes 
the amount of lipid observed in the lungs during 24 hours 
post administration was between 76%–106% of initial lipid 
dose suggesting that the lipids are not transported into the 
Table 2  AUC0 – 24 for pharmacokinetic data
Formulation Dose  (mg/kg)  AUC0 – 24 (μg/ml.hr)
Liposome-encapsulated  21.07 ± 1.64  8.02 ± 2.3
Ciproﬂ  oxacin   
AVT 1  17.05 ± 0.44  19.8 ± 0.12
AVT 2  18.31 ± 0.62  10.45 ± 0.92
AVT 2 + cysteine  18.56 ± 0.54  14.51 ± 2.3
0
10
20
30
40
50
60
70
80
90
0                 10                 20                30                 40                 50                 60
Time (hrs)
l
i
p
i
d
 
%
 
o
f
 
i
n
i
t
i
a
l
 
d
o
s
e
Fluorescent Liposomes
Fluorescent AVT 2
Fluorescent AVT 2 + cysteine
Figure 5 Percentage of original dosed lipid remaining in the lungs on the basis of ﬂ  uorescence assay of the tagged lipid. n = 3 animals.International Journal of Nanomedicine 2007:2(3) 417
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circulation. We therefore believe that the total lipid (as 
particles) is remaining in the lungs for the entire time of 
the experiment (48 hours), and that drug release from the 
particles into the lungs then results in the transport of free 
drug into the systemic circulation.
Conclusions
The aliphatic linker DTSSP creates a disulﬁ  de link in AVT 
particles that is cleavable by cysteine in vivo, triggering a 
ciproﬂ  oxacin release. Both the AVT particles and unag-
glomerated liposomes appear to remain in the lung for at 
least 48 hours after administration. The mechanism by which 
ciproﬂ  oxacin is delivered to the blood therefore appears to be 
(1) a release of ciproﬂ  oxacin from the particles into the lung 
ﬂ  uid, followed by (2) transport of the free ciproﬂ  oxacin into 
the bloodstream. Speciﬁ  cally, the transport of encapsulated 
ciproﬂ  oxacin into the blood is not suggested by our results. 
In contrast, previous work (Wong et al 2003) showed that 
liposomal ciproﬂ  oxacin was more effective than free cipro-
ﬂ  oxacin against intracellular pathogens such as F. tularensis, 
suggesting that liposomal drug was possibly transported 
intact into macrophages. However, the liposomal formula-
tions used by Wong were substantially different from those 
used in this work, and it is possible that changes in the bilayer 
composition affect the route of clearance from the lung.
While free ciproﬂ  oxacin administered to the lung resulted 
in signiﬁ  cant inﬂ  ammation, the liposomal and AVT formula-
tions did not. This suggests that the encapsulation effectively 
prevented the free drug from contacting the lung tissue in 
large amounts. Progressive release of the drug, however, does 
not cause signiﬁ  cant inﬂ  ammation either, since the overall 
free drug concentration at any time is low.
AVT particles also exhibited higher bioavailability than 
the liposomes, as indicated by the higher AUC for the AVT 
particles. This is somewhat counterintuitive, since one expects 
the higher surface area of the parent liposomes to result in 
higher release rates. However, we have previously observed 
this phenomenon in vitro, and it is believed that the larger AVT 
particles, being subject to larger shear forces in the lung, are 
being disrupted easier than the small liposomes. Thus, AVT 
particles are expected to have two mechanisms for drug release 
(1) diffusion of the drug out of the liposomes themselves, and 
(2) bulk leakage due to bilayer disruption. This mechanism is 
consistent with the repeated observation that AVT particles 
have higher systemic bioavailability than liposomes.
The two AVT formulations tested also had somewhat 
different bioavailabilities. While the reasons for this are 
yet unclear, they are probably related to the different size 
distributions of the two AVT particle formulations. The 
non-cleavable formulation AVT1 had larger particles than 
the cleavable AVT2. Thus, AVT1 had a higher release and 
bioavailability, while AVT2 had lower release and bioavail-
ability.
Cleavage of the links in AVT2 by the administration 
of exogenous cysteine causes an immediate increase in 
ciproﬂ  oxacin release. Further, the release rate appears to 
remain at this elevated level, reﬂ  ected in an increased blood 
concentration of ciproﬂ  oxacin at subsequent times. The 
cumulative release, measured by the AUC, is also higher 
for the cleaved formulation, consistent with this overall 
increased release rate.
The ability to accelerate release in vivo by the instillation 
of exogenous cysteine, cleaving the aliphatic disulﬁ  des link-
ing the AVT particles, is the most signiﬁ  cant ﬁ  nding of this 
work, facilitating post-administration modulation of the drug 
release rate. Thus, one envisions a treatment regimen wherein 
a patient could inhale a dose sufﬁ  cient for an extended period 
of time at a basal release rate, and periodically accelerate this 
release by the inhalation of a cleaving agent, thus achiev-
ing periodic elevations of the blood level of drug, without 
increasing the overall drug or excipient load.
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